FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/04/2026
Voltar para busca
Dado oficial do USPTO
XERVYTEG
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
28/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
21/03/2025
Data de registro
27/01/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/01/2026
Última transação
28/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
FR
Examinador
GLUECK, CHRISTOPHER N
Unidade examinadora
M30
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
M. P. (pessoa física)
Representantes
Pina M. Campagna Carter, DeLuca, & Farrell, LLP
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and biopharmaceutical products and preparations for the medical treatment of gastrointestinal diseases and disorders emanating from microbiota dysfunction; pharmaceutical and biopharmaceutical products and preparations used for the treatment of cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; pharmaceuticals used to maintain health or restore health to a human subject in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; biological preparations in the nature of microorganisms used to maintain health or restore health to a human subject in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases
Classe 10
Medical and surgical apparatus and instruments for use in gastrointestinal surgery; drug delivery devices in the nature of medical apparatus and instruments for administration of pharmaceutical and biopharmaceutical products and preparations, namely, a kit comprising a suspension bag and administration tube set, sold empty; Drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, namely, syringes, infusion sets, implantable devices sold empty; drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, in the nature of a kit comprising a prefilled suspension bag and administration tube set sold without medication
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
27/01/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
27/01/2026
GPNX
NOTIFICATION PROCESSED BY IB
11/12/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/12/2025
PUBO
PUBLISHED FOR OPPOSITION
09/12/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/12/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
26/11/2025
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
25/11/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
13/11/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/11/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
12/11/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/11/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
12/11/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/11/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/10/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/10/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
29/10/2025
RFNT
REFUSAL PROCESSED BY IB
30/08/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/08/2025
RFRR
REFUSAL PROCESSED BY MPU
07/08/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
21/06/2025
CNRT
NON-FINAL ACTION WRITTEN
20/06/2025
DOCK
ASSIGNED TO EXAMINER
18/06/2025
MAFR
APPLICATION FILING RECEIPT MAILED
22/05/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/05/2025
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
15/05/2025
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace XERVYTEG ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.